Navigation Links
Pivotal Study Shows Physician/Nurse Teams Using SEDASYS(TM) System Reduced Risk of Over Sedation With Propofol
Date:5/19/2008

SAN DIEGO, May 19 /PRNewswire/ -- DDW 2008 Annual Meeting -- Ethicon Endo-Surgery announced today that the results from its pivotal trial demonstrated physician/nurse teams using the SEDASYS(TM) System reduced the risk of over sedation with propofol in patients undergoing screening and diagnostic procedures for colorectal cancer (colonoscopy), and disorders of the upper gastrointestinal tract (EGD). The study -- which will be presented Tuesday at Digestive Disease Week(i) -- included 1,000 subjects who underwent sedation for colonoscopy and EGD at eight sites and compared the SEDASYS(TM) System to the current standard of care for sedation (midazolam plus fentanyl or meperidine). Results were included in Ethicon Endo-Surgery's PreMarket Application (PMA) for approval of the SEDASYS(TM) System, which is currently in review with the U.S. Food and Drug Administration.

"During the trial, the system made it possible for gastroenterologists to maintain minimal to moderate sedation with propofol, and helped prevent patients from entering deep sedation, which is traditionally associated with propofol," said Daniel Pambianco, MD, F.A.C.G., medical director of Charlottesville (Va.) Medical Research and trial investigator.* "The system offers a way to personalize the level of sedation appropriate for each patient because it combines propofol delivery with sophisticated monitoring to help us better control and predict the patient's sedation level."

Patients who received sedation with the SEDASYS(TM) System experienced fewer and less significant oxygen desaturation events, a clinical sign of over sedation, than patients sedated with current standard of care. The trial demonstrated this by achieving its primary endpoint of Area Under the Curve (AUC) of oxygen desaturation (SpO2 < 90%). AUC is an objective measure of a patient's respiratory status that incorporates incidence, duration and depth of oxygen desaturation. Patients in the SEDASYS(TM) System group ha
'/>"/>

SOURCE Ethicon Endo-Surgery
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Arbios Receives Approval From the FDA to Initiate Pivotal Trial for SEPET(TM) Liver Assist Device
2. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
3. BioVex Agrees SPA With the FDA for a Pivotal Study With OncoVEX(GM-CSF) in Metastatic Melanoma and Announces Presentation of Phase II Results at ASCO
4. Arpida Provides Further Comments on the Pivotal Phase III Trials
5. Anesiva Announces Pivotal Phase 3 Clinical Trial of Adlea(TM) for Reducing Post-Surgical Pain Following Total Knee Replacement
6. PLC Systems Receives FDA Approval to Commence Pivotal Study Of RenalGuard(TM) In the U.S.
7. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R) Following Second Interim Review
8. DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial
9. Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
10. Accumetrics Announces $28.8 Million Financing and Initiation of Pivotal Clinical Trial
11. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2008)...utomation and intelligent clinical applications ta... level , , CHICAGO, Ill., Nov. 26 /PRNewswi...ens.com/healthcare ) highlights the ACUSON S2000(...e world,s first multi-use, automated volume breast...y and Annual Meeting of the Radiological Society o...
(Date:11/25/2008)...against expanding statin use broadly in wake of AH...ov. 25 JUPITER, a clinical trial s...r risk of healthy patients with elevated CRP, shou..., according to a national poll directed at health ...n the online poll conducted by medical news site M...
(Date:11/25/2008)...l Trial to Assess Survival of Patients Receiving L...able Hepatocellular Carcinoma , , BELLEVUE,...ology, Inc. (LSO) today announced the completion o... Light Infusion Therapy(TM) (Litx(TM)) as a treatm...), also known as hepatoma or primary liver cancer....
(Date:11/24/2008)...swire-FirstCall/ -- Leaders of Schering-Plough Cor...or investors on the company,s research pipeline, h...ncludes 46 new entities in clinical trials or unde... , , "Research and development is adding st...ue our transformation," said Fred Hassan, chairman...
Breaking Medicine Technology:Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 2Dramatic JUPITER Findings Fail to Sway Prescribing Behavior, Poll Shows 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 2Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 3Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 4Schering-Plough Highlights R&D Pipeline Progress, Innovation and Breadth of Research Projects 5ViroPharma Receives European Orphan Drug Designation for CAMVIA 28TM 29 6092 1ViroPharma Receives European Orphan Drug Designation for CAMVIA 28TM 29 6092 2ViroPharma Receives European Orphan Drug Designation for CAMVIA 28TM 29 6092 3ViroPharma Receives European Orphan Drug Designation for CAMVIA 28TM 29 6092 4American Cancer Society Seeks Volunteers to Help Decide Who Gets Research Grants 6090 1American Cancer Society Seeks Volunteers to Help Decide Who Gets Research Grants 6090 2Researchers identify how to switch off cancer cell genes 1186 1Earth Observation essential for geohazard mitigation 1184 1Earth Observation essential for geohazard mitigation 1184 2Earth Observation essential for geohazard mitigation 1184 3
...n,s pipeline provide support for,epigenetic and co...,data on use of Thalidomide to treat multiple myel...tCall/ -- Pharmion,Corporation reported today that...he company,s marketed and pipeline products will b...f Clinical,Oncology,s (ASCO) 43rd Annual Meeting i...
...2007 - Introgen Therapeutics, Inc.,(NASDAQ:INGN) r...N,241, the Company,s novel investigational mda-7/I...nced solid tumors., The data (Abstract #380), whic...e American Society of Gene Therapy, showed that,in...n all treated,tumors, including in those patients ...
Other Medicine Technology:Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 2Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 3Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 4Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 5Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 6Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting 7Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 2Introgen Reports Promising Phase 1/2 Clinical Results With INGN 241,in Patients With Advanced Solid Tumors 3
(Date:12/1/2008)...news event -- Hall of States, Room 333 -- 444 Nort..., WASHINGTON, Dec. 1 ...oming together to outline the current fiscal situa...ext Administration to provide a recovery package t...rojects and ease the burden of Medicaid costs. As ...
(Date:12/1/2008)...wire/ -- An independent study at the,University o...want to play,video games at the same time as exer... , Fifty children aged 11 and 12 were asked...mes provided by a company called Gamercize. , ...they maintained movement on,the fitness machines....
(Date:12/1/2008)...Newswire/ -- Transcept Pharmaceuticals,Inc., a p...nounced today that,Glenn A. Oclassen, President &...ticipate at the RBC Capital Markets 2008 Healthcar... "Delivering Novel Drug Solutions: The Future of D... take place on Thursday, December,11, 2008 at 1:3...
(Date:12/1/2008)... Cardinal,Health and SR...ar supply and,co-marketing agreement to offer sur...oducts from Cardinal Health and reusable health ca...ment makes Cardinal Health the exclusive manufactu...400 disposable surgical kits. In,addition, the ag...
Breaking Medicine News(10 mins):Health News:Governors, Legislators Update Current State Fiscal Conditions, Push for Economic Recovery Package from Congress, President-elect 2Health News:Children Tell Researchers: We'll Get Fit if It's Fun 2Health News:Transcept Pharmaceuticals to Participate on Drug Delivery Investor Panel 2Health News:Cardinal Health, SRI Surgical Sign Five-Year Agreement For Surgical Kits 2Health News:Cardinal Health, SRI Surgical Sign Five-Year Agreement For Surgical Kits 3
...hKline (GSK) has reached an agreement with Eliot S... that it deceptively tried to delay competitors fr...-depressant drug Paxil.// GSK was allegedly inv... generic producers of Paxil in a bind of using fri...
...abani and his assistant Kartar Singh have been sen...of a fetus and then agreeing to abort it if it was... practitioner has been jailed for carrying out ill...ions. The perpetrators were found out when govern...
...onfections, Inc. of Dallas, Texas are tough nuts t...batch of production of Sam's Choice Belgian Milk C... almonds. This is a precautionary measure to ensur...ic to almonds that may cause a life threatening re...
... testing for HIV/AIDS in countries with high infec...er US president. // There was a stigma attached ...r those infected few decades ago and so AIDS testi... to Clinton, countries where there was no discrimi...
Other Medicine News:
The challenge for Carl Zeiss was to find innovative solutions for measurements on the eye and for preoperative computation of intraocular lenses (IOL). The result of this development work is the IOLM
Ahmed Glaucoma Valve (small size) with Pars Plana Clip .
Ahmed Glaucoma Valve.
...ompatibility is established. Provides a robust and...nsure correct positioning on the globe. Pressure R...h, when covered by Tenons tissue, acts as a Pressu...ive hypotony. The range of implants allows the sur...
Medicine Products: